ORIGINAL ARTICLE

The relationship of hormonal receptor, HER-2, and KI-67 changes after administration of anthracycline-based neoadjuvant chemotherapy with the results of histopathological grading in stage III breast cancer patients at Saiful Anwar Malang Regional Public H

Risal Wintoko , Hery Susilo

Risal Wintoko
Department of Surgery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. Email: risalwintoko.dr@gmail.com

Hery Susilo
Department of Surgery, Oncology Division, Faculty of Medicine, Universitas Brawijaya, Malang Indonesia
Online First: December 01, 2019 | Cite this Article
Wintoko, R., Susilo, H. 2019. The relationship of hormonal receptor, HER-2, and KI-67 changes after administration of anthracycline-based neoadjuvant chemotherapy with the results of histopathological grading in stage III breast cancer patients at Saiful Anwar Malang Regional Public H. Bali Medical Journal 8(3): S788-S794. DOI:10.15562/bmj.v8i3.1555


Background: Breast cancer is cancer, with the highest incidence in women worldwide. It also has a very high mortality due to late treatment. The immunohistochemical examination is an important factor in determining breast cancer subtypes and subsequent therapy. However, neoadjuvant chemotherapy (NACT) has been reported to change the expression of immunohistochemical examinations of Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor-2 (HER-2), and Ki-67. This study aims to determine the relationship between hormonal, HER-2, and KI-67 changes after NCAT.

Method: The immunohistochemical examinations were conducted on ER, PR, HER-2, Ki-67 and histopathological grading from 59 cases of stage III breast cancer after NACT administration. We analyzed the relationship between the changes in the expression of immunohistochemical examinations on the biopsy tissue specimens before NACT administration and from the tissue mastectomy after NACT administration associated with its histopathological grading with spearman correlation analysis using SPSS version 25 for Windows.

Results: There were changes in the results of the expression of immunohistochemical examinations of ER, PR, HER-2, KI-67 and histopathological grading by 23.7%, 22.03%, 32.2%, 32.2% and 40.68% in stage III breast cancer patients who received NACT. There was a relationship with a weak correlation between the changes in immunohistochemical examinations of ER, PR, HER-2 and KI-67 with the changes in histopathological grading. The correlation coefficients between ER, PR, HER-2, Ki-67 and the histopathological grading were r=0.265, r=0.317, r=0.352 and r=0.335.

Conclusions: Patients with stage III breast cancer who were treated with NACT experienced changes in the expression of immunohistochemical examinations of ER, PR, HER-2 and KI-67 and would experience changes in histopathological grading, causing changes in the breast cancer subtypes.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN. 2018;68:394–424

Basic Health Research (Riset Kesehatan Dasar/Rikesdas) of the Ministry of Health. Health Research and Development Agency, Indonesian Ministry of Health: South Jakarta. 2013

Gondhowiardjo S, Sekarutami SM, Poetiray EDC. Breast Cancer Treatment: The Role of Surgery and Irradiation. In: The Multidisciplinary Cancer Management of SolidTumors. Faculty of Medicine University of Indonesia; Jakarta. 2004:225-238

Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Front Oncol. 2018;8:227.

Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S,, et al. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012;13(6):e240-8.

Akhsan A, Aryandono T. Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy. Asian Pac J Cancer Prev. 2010;11(3):759-61.

Lestari AAW, Prabawa IPY, Wiranata S, Supadmanaba IGP. High eosinophilic lymphocyte ratio (ELR) related with subtype of breast cancer in Sanglah General Hospital. Annals of Oncology. 2018;29(suppl_9).

Wiranata S, Adiputra PAT, Lestari AAW, Prabawa IPY, Supadmanaba IPY. Platelet Lymphocyte Ratio (PLR) Related with Clinicopathological Characteristics of Balinese Women Breast Cancer Patient. Annals of Oncology. 2019;30(suppl_6).

Suyatno, Pasaribu ET. Surgical Oncology Diagnosis and Therapy. 2nd edition. Sagung Seto: Jakarta. 2014: 60-65

Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol. 2014;5(3):382-92.

Kaya AO, Buyukberber S, Yamac D, Coskun U, Yildis R, Yaman E, et al. Change in Hormon Receptor and Her-2 Status After Neoadjuvant Chemotherapy in Breast Cancer. 2010. Turkiye Klinikleri J Med Sci. 2010;30(2):469-473

Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, et al. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015;20(1):45-9.

Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-74

Rosai J, Ackerman. Clasification of Tumours pathology and genetic of tumours of Breast. In: Surgical pathology. 10th Ed. Toronto: Elsevier. Word Health Organization, Lyon: IARC Press. 2012

van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR.. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011;37(6): 422-430.

Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011;29(9):594-598.

Jin G, Han Y, Liu C, Chen L, Ding B, Xuan S, et al. Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer. Int J Clin Exp Pathol. 2015;8(1): 914-921.

Basak Oven Ustaalioglu B, Aker Vardar F, Bilici A, Gurleyik G, Erkol B, Kefeli U, et al. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer. J BUON. 2014;19(4):879-886.

Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92(1):147- 155.

Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM. Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor-positive Breast Cancer. Ann Surg Oncol. 2012;19(9): 3002-3011.

Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 2009;101(9):1529-36.

Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 2008;28(3B):1797 804

Ramteke P, Seenu V, Prashad R, Gupta SD, Iyer V, Deo S, et al. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India. Indian J Cancer. 2016;53(3):366-371.

Mannell A. The role of Ki-67 in breast cancer. S Afr J Surg. 2016;54(2):10-13.

Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, et al. Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer. Zhonghua Zhong Liu Za Zhi. 2009;31(11):858-62.

Tan QX, Qin QH, Yang WP, Lian B, Wei CY. Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients. Int J Clin Exp Pathol. 2014;7(7):4086-94.

Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015;33(24):2695-704

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601-8.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0